First-in-Class Modulators Identified for Two Highly-Valued Receptor Classes
Pelagos’ drug discovery programs are rationally-designed to modulate (agonize) two highly-validated receptor classes widely believed to be intractable (until now):
| Program | Target Validation | In Vivo POC | Lead Optimization | DC Nomination | IND-Enablement |
|---|---|---|---|---|---|
| Pan-ERR Modulator | Complete | Complete | In-Progress | Q4-2027 | 2028 |
| REV-ERB Modulator | Complete | Complete | In-Progress | Q3-2027 | 2028 |